| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_49cb04dcfb9a4c31f16b8ff446882c9f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f6f5b4dd97c2851ee92015656b4b4b23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2b5971ad2c41e1f82bb2a56de6ee2a2f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9b19b72246e7aecd39bb5db7964ec401
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae84948901b77f34fd51c41264d8d19c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a2e0ccb83f41f73e5a50061f1efe244f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 |
| filingDate |
2005-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc2c853b7499765dc65be4cd74fbd625
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75f66e96eba7226154a3fd25e0264bd0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75b3b9c45b76fbb5a31a63c00c41607f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd895c5261064b432d66ae273702e090 |
| publicationDate |
2006-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006067150-A1 |
| titleOfInvention |
Oral immediate release formulation of a poorly watersoluble active substance |
| abstract |
The invention is related to an oral immediate release formulation of Benzazepin -1- acetic acid derivatives comprising: a) said active substance in an amount of up to 65% of the total weight of the formulation; b) at least 10% w/w an alkaline compound or a mixture of alkaline compounds; c) between 0.1 and 10% of one or more surfactants, and d) optionally comprises auxiliary materials an amount of between 1% and 45% of the total weight of the formulation. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11413296-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2037890-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010144865-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-014898-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007144418-A1 |
| priorityDate |
2004-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |